Summary & Overview
HCPCS J0589: Injection, daxibotulinumtoxina-lanm, 1 unit
HCPCS Level II code J0589 denotes a per-unit charge for daxibotulinumtoxinA-lanm, an injectable neuromodulator product. Nationally, this code matters because it standardizes billing for a novel biologic agent used in neuromuscular and aesthetic indications, affecting reimbursement, utilization tracking, and coverage policy across commercial and federal payers. Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what J0589 represents clinically and operationally, how major payers commonly cover or categorize the product, and which practice settings typically administer the injection. The publication provides benchmarks for service lines and site-of-service patterns, summarizes common modifier use where available, and outlines relevant policy considerations that drive coding and claims processing for injectable biologics. Where input data is incomplete, the report notes that specific fields are unavailable. The focus is national: clinicians, billing staff, and policy analysts will gain a concise reference for coding J0589, understanding payer scope, and identifying where to look for coverage guidance and billing nuances for daxibotulinumtoxinA-lanm.
Billing Code Overview
HCPCS Level II code J0589 represents Injection, daxibotulinumtoxina-lanm, 1 unit. This code is used to report administration of daxibotulinumtoxinA-lanm as a per-unit injectable biologic product. The service type is an injectable neuromodulator/biologic administration, typically delivered via intramuscular or subcutaneous injection depending on clinical indication. The typical site of service is an outpatient clinic, ambulatory surgical center, or physician office.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult seeking treatment for moderate to severe glabellar lines, lateral canthal lines (crow’s feet), or cervical dystonia who presents to a dermatology, plastic surgery, or neurology clinic. After clinical evaluation documenting muscle hyperactivity and treatment goals, informed consent is obtained for injection of J0589 (daxibotulinumtoxina-lanm, 1 unit). The provider performs targeted intramuscular or intradermal injections using standardized dilution and dosing protocols. Site of service is commonly an outpatient clinic, ambulatory surgery center, or office-based procedure room. Vital signs and relevant precautions (neuromuscular disorders, pregnancy, active infection at injection site) are reviewed. The procedure is documented with units administered, injection sites, lot number, and any immediate adverse reactions. Post-procedure instructions and follow-up appointment scheduling are provided to assess efficacy and adverse events. Billing is submitted using HCPCS code J0589 with appropriate modifier(s) to reflect circumstances such as bilateral procedures, discontinued services, or provider/supplier status.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard, when no modifier applies |